Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, West Java, Indonesia.
Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, West Java, Indonesia.
Int J Nanomedicine. 2023 Sep 25;18:5473-5493. doi: 10.2147/IJN.S426120. eCollection 2023.
In 2020, there were 2.21 million new instances of lung cancer, making it the top cause of mortality globally, responsible for close to 10 million deaths. The physicochemical problems of chemotherapy drugs are the primary challenge that now causes a drug's low effectiveness. Solubility is a physicochemical factor that has a significant impact on a drug's biopharmaceutical properties, starting with the rate at which it dissolves and extending through how well it is absorbed and bioavailable. One of the most well-known methods for addressing a drug's solubility is mesoporous silica, which has undergone excellent development due to the conjugation of polymers and ligands that increase its effectiveness. However, there are still very few papers addressing the success of this discovery, particularly those addressing its molecular pharmaceutics and mechanism. Our study's objectives were to explore and summarize the effects of targeting mediator on drug development using mesoporous silica with and without functionalized polymer. We specifically focused on highlighting the molecular pharmaceutics and mechanism in this study's innovative findings. Journals from the Scopus, PubMed, and Google Scholar databases that were released during the last ten years were used to compile this review. According to inclusion and exclusion standards adjusted. This improved approach produced very impressive results, a very significant change in the characteristics of mesoporous silica that can affect effectiveness. Mesoporous silica approaches have the capacity to greatly enhance a drug's physicochemical issues, boost therapeutic efficacy, and acquire superb features.
2020 年，全球有 221 万例新的肺癌病例，是导致全球死亡率最高的疾病，导致近 1000 万人死亡。化疗药物的理化问题是导致药物疗效降低的主要挑战。溶解度是一个重要的理化因素，它会影响药物的生物制药特性，从药物的溶解速度，到药物的吸收和生物利用度。解决药物溶解度问题最常用的方法之一是介孔硅，由于聚合物和配体的结合提高了药物的有效性，介孔硅的发展非常出色。然而，仍然很少有论文探讨这一发现的成功，特别是那些探讨其分子药剂学和机制的论文。我们的研究目的是探索和总结使用介孔硅和功能化聚合物靶向调节剂对药物开发的影响。我们特别关注在这项研究的创新发现中突出分子药剂学和机制。根据调整后的纳入和排除标准，从 Scopus、PubMed 和 Google Scholar 数据库中检索了过去十年发表的期刊进行综述。该改进方法取得了非常令人印象深刻的结果，显著改变了介孔硅的特性，从而可能影响其疗效。介孔硅方法具有极大地改善药物理化问题、提高治疗效果和获得卓越特性的潜力。
